Donor type/graft source selection strategies based on disease status for paediatric acute myeloid leukemia transplantation
Authors:
- Yoshiko HashiiYHYoshiko Hashii
- Hiroyuki IshidaHIHiroyuki Ishida
- Daisuke TomizawaDTDaisuke Tomizawa
- Nao YoshidaNYNao Yoshida
- Masakatsu YanagimachiMYMasakatsu Yanagimachi
Preprint
- 17 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
In the absence of a human leukocyte antigen-matched sibling donor for paediatric patients with acute myeloid leukemia (AML) who underwent the first allogeneic hematopoietic cell transplantation (allo-HCT), the optimal donor type/graft source remain undetermined among donor types—haploidentical related donor (HRD) and matched unrelated donor (MUD)—as well as graft source—umbilical cord blood (UCB). This study aimed to determine the optimal donor type/graft source. The Japanese database on 441 recipients (median age, 6.0 years, range [0.0–15.0]) for HRD (n = 71), MUD (n = 111), and UCB (n = 259) was analyzed retrospectively. Regarding recipients in remission [complete remission (CR) 1 or CR2 at allo-HCT, n = 271], the rate of a composite endpoint consisting of extensive chronic graft-versus-host disease (cGVHD)- and leukemia-free survival (LFS)—extensive cGVHD-LFS—was not statistically significant among UCB, MUD, and HRD recipients. Regarding recipients not in remission (n =170), extensive cGVHD-LFS was significantly higher for MUD recipients than for UCB ( p = 0.007) and HRD ( p = 0.015) recipients. HRD, MUD, and UCB were optimal for recipients in remission, while MUD was optimal for recipients not in remission. Namely, the donor type/graft source needs to be selected based on disease status at HCT.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Disease Status and Interval between Hematopoietic Cell Transplantations Predict Outcome of Pediatric Patients Who Undergo Subsequent Transplantation for Relapsed Hematologic MalignancyTransplantation and Cellular Therapy, 2024
- Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission StatusTransplantation and Cellular Therapy, 2023
- Chronic graft-versus-host disease in pediatric patients: Differences and challengesBlood Reviews, 2023
- Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2022
- A Comparison of the Clinical Outcomes of Haploidentical Transplantation and Other Graft Sources in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-AnalysisClinical Lymphoma Myeloma and Leukemia, 2022
- Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trialLeukemia, 2019
- Acute Myeloid Leukemia in Children2018
- Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remissionBone Marrow Transplantation, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Impact of age on outcome of pediatric acute myeloid leukemiaCancer, 2006